Development of anti-viral agents using molecular modeling and virtual screening techniques.
Identifieur interne : 002155 ( Main/Merge ); précédent : 002154; suivant : 002156Development of anti-viral agents using molecular modeling and virtual screening techniques.
Auteurs : Johannes Kirchmair [Autriche] ; Simona Distinto ; Klaus Roman Liedl ; Patrick Markt ; Judith Maria Rollinger ; Daniela Schuster ; Gudrun Maria Spitzer ; Gerhard WolberSource :
- Infectious disorders drug targets [ 2212-3989 ] ; 2011.
Descripteurs français
- KwdFr :
- Antiviraux (), Antiviraux (métabolisme), Antiviraux (pharmacologie), Découverte de médicament, Humains, Modèles moléculaires, Produits biologiques (), Produits biologiques (métabolisme), Produits biologiques (pharmacologie), Relation quantitative structure-activité, Simulation de dynamique moléculaire, Simulation numérique, Tests de criblage à haut débit, Thérapie moléculaire ciblée.
- MESH :
- métabolisme : Antiviraux, Produits biologiques.
- pharmacologie : Antiviraux, Produits biologiques.
- Antiviraux, Découverte de médicament, Humains, Modèles moléculaires, Produits biologiques, Relation quantitative structure-activité, Simulation de dynamique moléculaire, Simulation numérique, Tests de criblage à haut débit, Thérapie moléculaire ciblée.
English descriptors
- KwdEn :
- Antiviral Agents (chemistry), Antiviral Agents (metabolism), Antiviral Agents (pharmacology), Biological Products (chemistry), Biological Products (metabolism), Biological Products (pharmacology), Computer Simulation, Drug Discovery, High-Throughput Screening Assays, Humans, Models, Molecular, Molecular Dynamics Simulation, Molecular Targeted Therapy, Quantitative Structure-Activity Relationship.
- MESH :
- chemical , chemistry : Antiviral Agents, Biological Products.
- chemical , metabolism : Antiviral Agents, Biological Products.
- chemical , pharmacology : Antiviral Agents, Biological Products.
- Computer Simulation, Drug Discovery, High-Throughput Screening Assays, Humans, Models, Molecular, Molecular Dynamics Simulation, Molecular Targeted Therapy, Quantitative Structure-Activity Relationship.
Abstract
Computational chemistry has always played a key role in anti-viral drug development. The challenges and the quickly rising public interest when a virus is becoming a threat has significantly influenced computational drug discovery. The most obvious example is anti-AIDS research, where HIV protease and reverse transcriptase have triggered enormous efforts in developing and improving computational methods. Methods applied to anti-viral research include (i) ligand-based approaches that rely on known active compounds to extrapolate biological activity, such as machine learning techniques or classical QSAR, (ii) structure-based methods that rely on an experimentally determined 3D structure of the targets, such as molecular docking or molecular dynamics, and (iii) universal approaches that can be applied in a structure- or ligand-based way, such as 3D QSAR or 3D pharmacophore elucidation. In this review we summarize these molecular modeling approaches as they were applied to fight anti-viral diseases and highlight their importance for anti-viral research. We discuss the role of computational chemistry in the development of small molecules as agents against HIV integrase, HIV-1 protease, HIV-1 reverse transcriptase, the influenza virus M2 channel protein, influenza virus neuraminidase, the SARS coronavirus main proteinase and spike protein, thymidine kinases of herpes viruses, hepatitis c virus proteins and other flaviviruses as well as human rhinovirus coat protein and proteases, and other picornaviridae. We highlight how computational approaches have helped in discovering anti-viral activities of natural products and give an overview on polypharmacology approaches that help to optimize drugs against several viruses or help to optimize the metabolic profile of and anti-viral drug.
DOI: 10.2174/187152611794407782
PubMed: 21303343
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001554
- to stream PubMed, to step Curation: 001554
- to stream PubMed, to step Checkpoint: 001509
- to stream Ncbi, to step Merge: 002288
- to stream Ncbi, to step Curation: 002288
- to stream Ncbi, to step Checkpoint: 002288
Links to Exploration step
pubmed:21303343Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of anti-viral agents using molecular modeling and virtual screening techniques.</title>
<author><name sortKey="Kirchmair, Johannes" sort="Kirchmair, Johannes" uniqKey="Kirchmair J" first="Johannes" last="Kirchmair">Johannes Kirchmair</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmaceutical Chemistry, Faculty of Chemistry and Pharmacy, University of Innsbruck, Innrain 52, A-6020 Innsbruck, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Pharmaceutical Chemistry, Faculty of Chemistry and Pharmacy, University of Innsbruck, Innrain 52, A-6020 Innsbruck</wicri:regionArea>
<wicri:noRegion>A-6020 Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Distinto, Simona" sort="Distinto, Simona" uniqKey="Distinto S" first="Simona" last="Distinto">Simona Distinto</name>
</author>
<author><name sortKey="Liedl, Klaus Roman" sort="Liedl, Klaus Roman" uniqKey="Liedl K" first="Klaus Roman" last="Liedl">Klaus Roman Liedl</name>
</author>
<author><name sortKey="Markt, Patrick" sort="Markt, Patrick" uniqKey="Markt P" first="Patrick" last="Markt">Patrick Markt</name>
</author>
<author><name sortKey="Rollinger, Judith Maria" sort="Rollinger, Judith Maria" uniqKey="Rollinger J" first="Judith Maria" last="Rollinger">Judith Maria Rollinger</name>
</author>
<author><name sortKey="Schuster, Daniela" sort="Schuster, Daniela" uniqKey="Schuster D" first="Daniela" last="Schuster">Daniela Schuster</name>
</author>
<author><name sortKey="Spitzer, Gudrun Maria" sort="Spitzer, Gudrun Maria" uniqKey="Spitzer G" first="Gudrun Maria" last="Spitzer">Gudrun Maria Spitzer</name>
</author>
<author><name sortKey="Wolber, Gerhard" sort="Wolber, Gerhard" uniqKey="Wolber G" first="Gerhard" last="Wolber">Gerhard Wolber</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2011">2011</date>
<idno type="RBID">pubmed:21303343</idno>
<idno type="pmid">21303343</idno>
<idno type="doi">10.2174/187152611794407782</idno>
<idno type="wicri:Area/PubMed/Corpus">001554</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001554</idno>
<idno type="wicri:Area/PubMed/Curation">001554</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001554</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001509</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001509</idno>
<idno type="wicri:Area/Ncbi/Merge">002288</idno>
<idno type="wicri:Area/Ncbi/Curation">002288</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002288</idno>
<idno type="wicri:Area/Main/Merge">002155</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Development of anti-viral agents using molecular modeling and virtual screening techniques.</title>
<author><name sortKey="Kirchmair, Johannes" sort="Kirchmair, Johannes" uniqKey="Kirchmair J" first="Johannes" last="Kirchmair">Johannes Kirchmair</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmaceutical Chemistry, Faculty of Chemistry and Pharmacy, University of Innsbruck, Innrain 52, A-6020 Innsbruck, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Pharmaceutical Chemistry, Faculty of Chemistry and Pharmacy, University of Innsbruck, Innrain 52, A-6020 Innsbruck</wicri:regionArea>
<wicri:noRegion>A-6020 Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Distinto, Simona" sort="Distinto, Simona" uniqKey="Distinto S" first="Simona" last="Distinto">Simona Distinto</name>
</author>
<author><name sortKey="Liedl, Klaus Roman" sort="Liedl, Klaus Roman" uniqKey="Liedl K" first="Klaus Roman" last="Liedl">Klaus Roman Liedl</name>
</author>
<author><name sortKey="Markt, Patrick" sort="Markt, Patrick" uniqKey="Markt P" first="Patrick" last="Markt">Patrick Markt</name>
</author>
<author><name sortKey="Rollinger, Judith Maria" sort="Rollinger, Judith Maria" uniqKey="Rollinger J" first="Judith Maria" last="Rollinger">Judith Maria Rollinger</name>
</author>
<author><name sortKey="Schuster, Daniela" sort="Schuster, Daniela" uniqKey="Schuster D" first="Daniela" last="Schuster">Daniela Schuster</name>
</author>
<author><name sortKey="Spitzer, Gudrun Maria" sort="Spitzer, Gudrun Maria" uniqKey="Spitzer G" first="Gudrun Maria" last="Spitzer">Gudrun Maria Spitzer</name>
</author>
<author><name sortKey="Wolber, Gerhard" sort="Wolber, Gerhard" uniqKey="Wolber G" first="Gerhard" last="Wolber">Gerhard Wolber</name>
</author>
</analytic>
<series><title level="j">Infectious disorders drug targets</title>
<idno type="eISSN">2212-3989</idno>
<imprint><date when="2011" type="published">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (chemistry)</term>
<term>Antiviral Agents (metabolism)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Biological Products (chemistry)</term>
<term>Biological Products (metabolism)</term>
<term>Biological Products (pharmacology)</term>
<term>Computer Simulation</term>
<term>Drug Discovery</term>
<term>High-Throughput Screening Assays</term>
<term>Humans</term>
<term>Models, Molecular</term>
<term>Molecular Dynamics Simulation</term>
<term>Molecular Targeted Therapy</term>
<term>Quantitative Structure-Activity Relationship</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux ()</term>
<term>Antiviraux (métabolisme)</term>
<term>Antiviraux (pharmacologie)</term>
<term>Découverte de médicament</term>
<term>Humains</term>
<term>Modèles moléculaires</term>
<term>Produits biologiques ()</term>
<term>Produits biologiques (métabolisme)</term>
<term>Produits biologiques (pharmacologie)</term>
<term>Relation quantitative structure-activité</term>
<term>Simulation de dynamique moléculaire</term>
<term>Simulation numérique</term>
<term>Tests de criblage à haut débit</term>
<term>Thérapie moléculaire ciblée</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antiviral Agents</term>
<term>Biological Products</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antiviral Agents</term>
<term>Biological Products</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Biological Products</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Antiviraux</term>
<term>Produits biologiques</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Produits biologiques</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Computer Simulation</term>
<term>Drug Discovery</term>
<term>High-Throughput Screening Assays</term>
<term>Humans</term>
<term>Models, Molecular</term>
<term>Molecular Dynamics Simulation</term>
<term>Molecular Targeted Therapy</term>
<term>Quantitative Structure-Activity Relationship</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Antiviraux</term>
<term>Découverte de médicament</term>
<term>Humains</term>
<term>Modèles moléculaires</term>
<term>Produits biologiques</term>
<term>Relation quantitative structure-activité</term>
<term>Simulation de dynamique moléculaire</term>
<term>Simulation numérique</term>
<term>Tests de criblage à haut débit</term>
<term>Thérapie moléculaire ciblée</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Computational chemistry has always played a key role in anti-viral drug development. The challenges and the quickly rising public interest when a virus is becoming a threat has significantly influenced computational drug discovery. The most obvious example is anti-AIDS research, where HIV protease and reverse transcriptase have triggered enormous efforts in developing and improving computational methods. Methods applied to anti-viral research include (i) ligand-based approaches that rely on known active compounds to extrapolate biological activity, such as machine learning techniques or classical QSAR, (ii) structure-based methods that rely on an experimentally determined 3D structure of the targets, such as molecular docking or molecular dynamics, and (iii) universal approaches that can be applied in a structure- or ligand-based way, such as 3D QSAR or 3D pharmacophore elucidation. In this review we summarize these molecular modeling approaches as they were applied to fight anti-viral diseases and highlight their importance for anti-viral research. We discuss the role of computational chemistry in the development of small molecules as agents against HIV integrase, HIV-1 protease, HIV-1 reverse transcriptase, the influenza virus M2 channel protein, influenza virus neuraminidase, the SARS coronavirus main proteinase and spike protein, thymidine kinases of herpes viruses, hepatitis c virus proteins and other flaviviruses as well as human rhinovirus coat protein and proteases, and other picornaviridae. We highlight how computational approaches have helped in discovering anti-viral activities of natural products and give an overview on polypharmacology approaches that help to optimize drugs against several viruses or help to optimize the metabolic profile of and anti-viral drug.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002155 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 002155 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Main |étape= Merge |type= RBID |clé= pubmed:21303343 |texte= Development of anti-viral agents using molecular modeling and virtual screening techniques. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:21303343" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |